What Is the Innovation?
Kabashin and his colleagues reported recently in Nature Materials that label-free optical transduction technology has "at its core" surface plasmon resonance (SPR) (1 ) . In SPR, scientists monitor the refractive index to observe the binding of a ligand to its receptor in real time. A newer offspring of SPR, localized plasmon resonance (LPR), in which SPR occurs in nanostructures, is full of potential-from detecting low molecular weight molecules to optical tweezing. But don't order the balloons for the party just yet-there is a problem.
Conventional SPR is "two orders of sensitivity lower to label-based techniques," says Kabashin. And conventional LPR? Its sensitivity is inferior by 3 to 4 orders of magnitude compared with labeling methods. Why? "Well, nature has its limits," says Kabashin. At the heart of SPR and LPR are noble metals, usually gold. When gold is used, "inherent losses in the metallic nanostructures" prevent users from achieving total darkness. And optics, said Kabashin, is a "dark sport."
These factors led the team to think of creating a metamaterial nanostructure that would allow them to achieve topologically protected darkness. In short, the innovation is a biosensor with a metamaterial nanostructure that uses phase shifts to detect molecule binding in real time. To achieve this feat, the scientists use metaatoms arranged in a periodical quasicrystalline structure to attain complete darkness.
How Does It Work?
In SPR, surface plasmons, or oscillations of electrons that exist at the interface of 2 materials such as a metal and a dielectric material, may be excited by incident light that matches the momentum of the surface plasmon. The angle of reflection will change, depending on the presence of molecules adsorbed to the material. Because the phase change of the incident light is dependent on the adsorbed molecules, its measurement is a detection method used in SPR.
An important basic concept behind the investigators' innovation derives from Young's double-slit experiment, which you may recall from your elementaryphysics classes. In that experiment, coherent light passed through 2 slits interferes constructively (to create bright bands) and destructively (to create dark bands). The dark bands, also known as lines of optical singularity, are black lines where complete destructive interference occurs.
The team's innovation of using of a variety of tunable periodic plasmonic arrays allowed them to achieve almost complete darkness. For example, they were able to tune the array to obtain nearly complete darkness at a specific resonant wavelength and angle of incidence. Near this tuned wavelength and angle, the investigators demonstrated mathematically and experimentally that the phase sensitivity increases dramatically (2 ) . "The periodicity of the arrays [was] chosen in such a way that at [a] certain wavelength and incident angle a diffracted ray becomes grazing and couples the LPR of individual nanostructures . . . [leading] to a narrow collective plasmonic resonance which is very sensitive to the environment," write the authors. In fact, the phase jump at complete darkness-the optical singularity-is so sharp that the authors recommend working very closely to that point, but not right at it, to maximize the sensitivity.
To test phase sensitivity in their plasmonic structures, Kabashin and his team studied graphene hydrogenation, a material with well-known properties and that proved to be a reliable control (Fig. 1) . Indeed, when graphene was deposited on the gold-based metamaterial, complete darkness was observed at 69 degrees, which Kabashin said was expected. They exposed graphene to potential hydrogenation events, confirmed that binding occurs, and observed a phase shift of 44 degrees. The authors then tested the biosensing ability of their system on a streptavidin-biotin model. "In our estimations we did not have a low-noise system to achieve a real limit of detection," writes Kabashin in an e-mail message to Clinical Chemistry. Instead, they used "estimations of the detection limit based on values of phase resolution known from the literature." From that, they estimated a detection limit of 0.4 -2 streptavidin molecules per nanodot. The investigators reported a real mass sensitivity down to the femtogram-per-square-millimeter range for all models. "We can really resolve this number, and this is a strength of the proposed method," writes Kabashin.
Where Can This Technology Fit in the Clinical Laboratory?
"They've got one of the better sensors I've seen," says Bowers of the USADA. Increasing sensitivity has 2 benefits to his field of drug testing, according to Bowers. Such sensors can detect lower analyte concentrations, and the sizes of clinical samples for detection can be small.
Kabashin and his team agree that the strength of their sensor lies in its potential to detect lower analyte concentrations, a feature that could be applied to the early detection of disease, such as malaria or tuberculosis, or it could be used in drug discovery by documenting the amount of a potential drug binding to its target site.
One of the other uses suggested for the optics team's LPR technique is testing athletes for doping (3 ) . Bowers points out, however, that some hard science needs to be worked out before his field can use this technology. He says that the success of a biosensor does not hinge solely on sensitivity; it also depends on the biosensor's ability to inform researchers what they are observing. "The sensor is intriguing, but the difficulty in analysis is not in the sensor, but how you recognize the protein or peptide," says Bowers. For example, one of the most popular doping practices is the use of exogenous performance-enhancing recombinant erythropoietin, which is otherwise naturally produced in the body as a red blood cell stimulant. What the sports community is trying to do, according to Bowers, is to detect the difference between "a recombinant protein and native protein." "The challenge is how to sort through two populations of a closely related analyte that we're trying to deal with," says Bowers. "That is not a sensor issue; that is a biorecognition issue."
For Kabashin, one of the things he is most excited about is not purely diagnostics; rather, it is creating a technique that offers a real-time window into kinetic reactions. "We can supply biologists and chemists with additional channels," he says, for observing the world. 
